Home › Compare › SDTHF vs ABBV
SDTHF yields 9.51% · ABBV yields 3.12%● Live data
📍 SDTHF pulled ahead of the other in Year 1
Combined, SDTHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SDTHF + ABBV for your $10,000?
Sdiptech AB (publ) provides technical products and services for infrastructures in Sweden, the United Kingdom, Germany, Croatia, Austria, Norway, Finland, and internationally. The company operates through three segments: Water & Energy, Special Infrastructure Solutions, and Property Technical Services. It engages in the service, renovation, modernization, and new construction, as well as renovation of roof. The company also provides water and sewage treatment, water systems, and water purification services; power supply, electrical automation, and temporary electricity services; air and climate control products and services to monitor and control indoor climate, air quality, and energy efficiency. In addition, it offers safety and security services for secure communication and integrated security systems in public and private environments; and digital technology for speed monitoring and infrastructure for air traffic communication. Sdiptech AB (publ) was founded in 2004 and is based in Stockholm, Sweden.
Full SDTHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.